NuVasive to Present at the 8th Annual Needham Life Sciences Conference

llrx-royce.blogspot.com
A live webcast of the presentation will be available onlinse from the investor relationsz page ofthe Company's corporate website at . Afterd the live webcast, the presentation will remaim available on the website for 30 NuVasive is a medical devicr company focused onthe design, and marketing of products for the surgical treatmentr of spine disorders. The Company's product portfolio is focused primarilty onthe $4.6 billion U.S. spinwe implant market. Additionally, the Company has expanded intothe $1.5 billionm global biologics market, the $1.5 billionh international market, and is developinyg products for the emerging motionm preservation market.
NuVasive's principal producg offering is based on its MaximumAccesss Surgery, or MAS(R) platform. The MAS platformk combines four categories of products that collectively minimize soft tissuwe disruption during spine surgery with maximum visualization and easy reproducibility forthe surgeon: NeuroVision(R), a proprietar y software-driven nerve avoidance system; a unique split-blade retractoer system; a wide variety of specializedx implants; and several biologic fusion enhancers. MAS significantl reduces surgery time and returns patients to activitiess of daily living much faster thanconventional approaches.
Havin g redefined spine surgery with theMAS platform'ds lateral approach, known as eXtreme Lateral Interbody or XLIF(R), NuVasive has built an entirr spine franchise. With nearly 50 products today spanninb lumbar, thoracic and cervical applications, the Company will continue to expandx and evolve its offering predicaterd onits R&D focus and dedication to outstanding servicee levels supported by a culture of Absolute Responsiveness(R).
NuVasives cautions you that statements includec in this press release that are not a description of historicakl factsare forward-looking statements that involve uncertainties, assumptions and other factors which, if they do not materializd or prove correct, could cause NuVasive's results to differ materiallg from historical results or those expressed or impliefd by such forward-looking statements.
The potential risks and uncertainties that coulds cause actual growth and results to diffetmaterially include, but are not limited to: the uncertainj process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantlyg delayed; the possibility that the FDA may requirde significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market positioj enabling more successful commercialization; the risk that additionalp clinical data may call into question the benefits of NuVasive's products to hospitals and surgeons; and other risks and uncertainties more fully describexd in NuVasive's press releasesz and periodic filings with the Securities and Exchang Commission.
NuVasive's public filings with the Securities and Exchange Commission are availableat . NuVasive assumes no obligation to updateany forward-lookingy statement to reflect events or circumstanced arising after the date on whicjh it was made. Contact: Investors: Kevin C. O'Boyle Patricmk F. Williams EVP & Chief Financiao Officer Vice President, Finance Investor Relations NuVasive, Inc. NuVasive, Inc. 858-909-1998 858-638-5511 investorrelations@nuvasive.com investorrelations@nuvasive.com Media: Jason Rando The Ruth Grouo 646-536-7025 jrando@theruthgroup.com SOURCE NuVasive, Inc.